BioVie Says Recently Completed Funding Round Provides Opportunity To Further Its Clinical Priorities In Parkinson's Disease, Alzheimer's Disease, And Ascites/Liver Disease, The Company Continues To Explore Longevity And Aging In Conjunction With Partners
BioVie Says Recently Completed Funding Round Provides Opportunity To Further Its Clinical Priorities In Parkinson's Disease, Alzheimer's Disease, And Ascites/Liver Disease, The Company Continues To Explore Longevity And Aging In Conjunction With Partners
BioVie表示，最近完成的一轮融资为进一步推进其在帕金森氏病、阿尔茨海默氏病和腹水/肝病方面的临床重点提供了机会，该公司将继续与合作伙伴一起探索寿命和衰老
BioVie Says Recently Completed Funding Round Provides Opportunity To Further Its Clinical Priorities In Parkinson's Disease, Alzheimer's Disease, And Ascites/Liver Disease, The Company Continues To Explore Longevity And Aging In Conjunction With Partners
BioVie表示，最近完成的一轮融资为进一步推进其在帕金森氏病、阿尔茨海默氏病和腹水/肝病方面的临床重点提供了机会，该公司将继续与合作伙伴一起探索寿命和衰老
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。